
Tick bites are nearly double already this year. Will this summer be the worst yet?
But, is it the worst ever?
University of Rhode Island entomologist Dr. Thomas 'The TickGuy' Mathers told The Independent that it's too early to call it but the numbers are looking worrying — he's received more submissions of nymphal blacklegged ticks, which carry Lyme disease, to the university's TickSpotters platform so far this month than the weekly average for the same period over the last decade.
'I don't know the answer just yet, if it's a trend going up – but I suspect it is, just based on the number of nymphal blacklegged ticks I've seen in the past couple of weeks,' he explained.
Mathers noted that federal data shows emergency room visits related to ticks are up this year, with visits nearly doubling from 70 in April, to 131 in May.
Other researchers who also count ticks are noticing a significant jump in specimens.
Dr. Saravanan Thangamani, a professor at New York's SUNY Upstate Medical University who runs the Upstate Tick Testing Laboratory, has warned that more ticks are being sent to the lab than at the same time last year, marking a 217 percent increase.
'Based on the trend in tick submission I have observed thus far, I expect a tick season that is worse than the previous years,' he cautioned.
But, Rutgers University professor and entomologist Dina Fonseca is not ready to make that call quite yet. She's a part of the submission project called New Jersey Ticks 4 Science!
She said people say it's the worst year for ticks every year, noting there's no standardized tick surveillance. They're seeing more submissions, as well, but they don't know if it's just because more people are reporting them.
'Frankly, we don't have enough data over time to be able to say, 'Is it a worse year than normal or a better year than normal?' We don't know,' explained Fonseca.
What threats do US ticks pose?
Whatever the case may be, the heightened activity between June and July leaves Americans exposed to 90 species of ticks and the diseases they can carry. Although ticks are on both coasts, they're largely found in the eastern U.S. Some, like brown dog ticks and blacklegged ticks, are located more widely.
Not being prepared for ticks while doing outside activities and camping could carry a death sentence — although that's an extremely rare outcome.
People bitten by ticks may be exposed to Powassan virus, Babesiosis, Anaplasmosis, Tularemia, Lyme disease, and other pathogens that can cause human disease. People can be affected by multiple diseases at once.
The nymphal blacklegged ticks are the ones Fonseca says people really need to worry about, as they can be infected with four different disease agents. That includes Lyme disease, which may lead to facial paralysis and irregular heartbeat if untreated.
Although larger than larval ticks, nymphal ticks are only the size of a poppy seed. They may be hard to spot – even for people who are aware of their region's ticks and where they live.
'Look at the bowtie of Lincoln on a penny; that's the size of a nymphal blacklegged tick, Fonseca said.
Exposure and prevention
While it's easy to miss ticks, it can take about two days for any transmission to occur after a bite. People who find ticks on their skin should remove them with tweezers as soon as possible. Those who develop a rash or fever after removal should consult a doctor.
As far as prevention goes, knowledge is power. Reducing exposure is the best way to avoid negative health outcomes. Mather advises that people follow what he calls the 'three Ts.' Wear tight clothing, tuck in shirts and pants legs, and wear clothes treated with 0.5 percent permethrin repellent.
'If you don't apply repellent, they can be ruthless,' Fonseca said, recalling a time when she picked 30-to-40 ticks out of her hair. Mathers remembers a trip to Fire Island that resulted in the exposure to 'literally hundreds' of fast-crawling ticks.
Unfortunately, with a changing climate comes additional chances to pick up the blood-sucking hitchhikers. With a warmer atmosphere comes a wetter world, and parasites thrive in those conditions, and ticks have been observed moving north. Southern aridity is their enemy.
'One of the easiest ways to kill a tick is to dry the heck out of them,' said Fonseca.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


The Independent
27 minutes ago
- The Independent
Alien worlds may not necessarily need water, scientists find: ‘We just opened a Pandora's box'
Water may not be essential to support life, and an entirely different type of liquid could do the same in alien worlds, a new study claims. Until now, water has been considered a requirement for life on other worlds, with scientists defining the habitability of other planets based on its presence. However, a new lab experiment suggests salts existing in liquid form at lower temperatures in other worlds may host life, though unlike anything resembling Earth 's water-based beings. Such liquid-salts, called ionic liquids, can exist below about 100 degrees Celsius and remain stable enough in the fluid state at wider conditions to be a hospitable environment for life-signature molecules like proteins, say researchers from the Massachussets Institute of Technology. The study, published in the journal PNAS, theorises that even planets that are too warm, or those with atmospheres at pressures too low to host liquid water, could still support pockets of ionic liquid. 'We consider water to be required for life because that is what's needed for Earth life. But if we look at a more general definition, we see that what we need is a liquid in which metabolism for life can take place,' says Rachana Agrawal, an author of the study from MIT. 'Now if we include ionic liquid as a possibility, this can dramatically increase the habitability zone for all rocky worlds,' Dr Agrawal said. On Earth, such ionic liquids are mainly only made for industries, and do not occur naturally – except for one natural case. One liquid salt is generated from the mixing of venoms produced by two rival species of ants. In the new study, scientists sought to understand the broad conditions under which ionic liquids can be naturally produced, including the range of temperatures and pressures. They started by mixing sulphuric acid with 30 different nitrogen-containing organic compounds across several temperatures and pressures. Researchers then observed whether an ionic liquid formed when they evaporated away the sulphuric acid in various vials. This work was based on previous work suggesting that some of these chemicals, considered ingredients associated with life, are surprisingly stable in sulphuric acid. Scientists also mixed the ingredients onto basalt rocks, which are known to exist on the surface of many rocky planets. 'We were just astonished that the ionic liquid forms under so many different conditions,' says Sara Seager, another author of the study. 'If you put the sulphuric acid and the organic on a rock, the excess sulphuric acid seeps into the rock pores, but you're still left with a drop of ionic liquid on the rock. Whatever we tried, ionic liquid still formed,' Dr Seager says. Researchers found that their reactions produced ionic liquid at temperatures up to 180 degrees Celsius and at extremely low pressures – much lower than that of the Earth's atmosphere. The findings suggest ionic liquids can naturally form on other planets where liquid water cannot exist, under the right conditions. 'We're envisioning a planet warmer than Earth, that doesn't have water, and at some point in its past or currently, it has to have had sulphuric acid, formed from volcanic outgassing,' Dr Seager says. 'This sulphuric acid has to flow over a little pocket of organics. And organic deposits are extremely common in the solar system,' she explained. Scientists hope to conduct further studies to see what life-signature molecules might survive and thrive in ionic liquids. 'We just opened up a Pandora's box of new research. It's been a real journey,' Dr Seager said.


Daily Mail
an hour ago
- Daily Mail
The race to link our brains with AI: Inside Elon Musk and Sam Altman's battle to be first to connect mind and machine
The tussles between billionaires have seen vast fortunes splashed on everything from rocket ships to social media empires. But now, two titans of big tech are taking their fight to a frontier: The race to link our brains with AI. Tesla and xAI CEO Elon Musk and Sam Altman of OpenAI, the company behind ChatGPT, are vying to be the first to connect mind and machine. The former allies are now both backing rival companies trying to build brain-computer-interface (BCI) chips and put them inside humans. These devices allow people to directly control computers with their thoughts by reading the electrical signals produced in the brain. As outspoken champions of the technology, both Mr Musk and Mr Altman claim that BCIs will one day allow humanity to merge with artificial intelligence. Elon Musk's Neuralink, widely seen as the leader in the BCI field, has already tested its brain chips on patients in the US and has secured plans for UK trials. However, as reported by the Financial Times, Mr Altman is now planning to back rival firm Merge Labs with a plan to make BCIs faster and more capable using AI. Not too long ago, Musk and Altman were close collaborators who co-launched OpenAI in 2015, with Musk providing the majority of the funds. However, the pair fell out three years later after Musk dramatically quit the board following an internal battle for control over the fast-growing firm. In the following years, Musk and Altman have waged an increasingly public rivalry. This culminated in Musk suing OpenAI to prevent the company from transitioning into a for-profit, alleging a 'deceit of Shakespearean proportions'. As Musk attempts to challenge OpenAI's supremacy in AI with his problem-plagued chatbot, Grok, the former colleagues are now shifting their rivalry into the world of BCIs. BCIs use AI to convert the patterns of electrical activity found in the brain into commands that a computer can understand. Advocates argue that they have the potential to help disabled people recover their independence by remotely controlling computers, bionic limbs, or mobility aids. This technology has even gained the attention of governments, with the UK's Advanced Research and Invention Agency exploring its potential as part of a mission to explore devices that could change the world. Likewise, the Chinese Ministry of Industry and Information Technology has revealed its own BCI, used to restore hand movement in paralysed patients. Neuralink, which was founded in 2016, is leading the field for computer-brain connection research while rival startups, such as Precision Neuroscience, vie to compete. Neuralink uses a coin-sized computer chip containing 1,000 electrodes, separated into 128 tiny 'threads' each thinner than a human hair. Using a robotic surgeon, also being developed by Neuralink, the chip is placed on the surface of the brain, and the threads are inserted into the neural tissue. The chip, known as the N1, uses these electrode threads to record huge amounts of data on the brain's activity and uses AI to translate those signals. Neuralink began human trials in America last year, implanting a chip into its first human volunteer, Noland Arbaugh, who was paralysed from the neck down in a driving accident. Using the chip, Mr Arbaugh regained the ability to control a computer, enabling him to write, play chess, and even play complex video games. Since then, the company has implanted chips in a further six participants in the United States and recently received approval to recruit a further seven patients for a British study, the first of its kind in Europe. Neuralink has now implanted chips into seven patients in the United States, including Audrey Crews (pictured), who has been paralysed since she was 16 Recently, the company raised $650 million (£478m) in a funding deal, which gave it a valuation of $9 billion (£6.63bn). By contrast, very little is known about Mr Altman's rival firm, Merge Labs. Mr Altman reportedly plans to launch the company alongside his long-term collaborator Alex Blania, who runs the Altman-backed eyeball scanning digital ID project, Worldcoin. It is expected that Mr Altman will help found the company, but won't have a day-to-day role in its operations. The exact form of BCI technology Merge Labs plans to pursue remains a mystery; beyond the fact that it will make the most of recent AI advances to improve BCI function. Merge Labs is reportedly seeking $250 million (£184m) in initial funding, much of which is expected to be provided by OpenAI's ventures arm, giving the company an initial valuation of $850 million (£625m). However, despite their rivalry, both Mr Musk and Mr Altman appear to be pursuing BCI technology with a similar goal in mind. Mr Musk has said that his ambition is to make a 'general population device' that will allow for 'symbiosis with artificial intelligence'. Sam Altman wrote in a 2017 blog that merging with AI was the only way to avoid fading into an, 'evolutionary tree branch' as AI overtakes human intelligence The billionaire X owner has also insinuated that merging with computers is necessary to prevent super-intelligent AI from getting out of control. Similarly, Mr Altman wrote in a 2017 blog post titled 'The Merge' that humans and machines would become one between 2025 and 2075. In the blog, Mr Altman wrote: 'The merge can take a lot of forms: We could plug electrodes into our brains, or we could all just become really close friends with a chatbot. But I think a merge is probably our best-case scenario. 'My guess is that we can either be the biological bootloader for digital intelligence and then fade into an evolutionary tree branch, or we can figure out what a successful merge looks like.' Elon Musk's Neuralink is working to link the human brain with a machine interface by creating micron-sized devices. Neuralink was registered in California as a 'medical research' company in July 2016, and Musk has funded the company mostly by himself. It is working on what Musk calls the 'neural lace' technology, implanting tiny brain electrodes that may one day upload and download thoughts. The technology is initially planned to be used to help people suffering from severe degenerative brain disorders such as ALS, but it could have wider uses in years to come.


Reuters
an hour ago
- Reuters
THL Partners to acquire clinical trial firm Headlands from KKR, sources say
NEW YORK, Aug 14 (Reuters) - Private equity firm THL Partners has agreed to buy a majority stake in Headlands Research, a U.S.-based network of clinical trial sites, from KKR (KKR.N), opens new tab in a deal valued at about $600 million, according to people familiar with the matter. The transaction could be announced as soon as Thursday, the sources said. Clinical trial sites are experiencing steady business growth as pharmaceutical companies ramp up research spending, driven by new types of therapies and the growing healthcare needs of an aging population. Private equity firms have stepped up their involvement in clinical trials, drawn by the potential to leverage technology to scale operations and consolidate a fragmented network of stand-alone sites into more integrated and valuable platforms. THL has been active in pharma services for more than two decades, with past investments including Syneos Health, PCI Pharma Services, Adare Pharma Solutions, and Red Nucleus. The transaction marks an exit for private equity firm KKR, which acquired Headlands in 2018 and is said to have at least doubled its investment, according to a person familiar with the matter. KKR's exit in Headlands followed its successful $12 billion divestment of PRA Health Sciences, a clinical research organization where it delivered a sixfold return for investors. Recent deals by private equity firms in clinical trials include BayPine's $1.5 billion acquisition of CenExel, and Genstar Capital's majority investment in Flourish Research, for an undisclosed amount. AI is accelerating drug discovery and development, and private equity firms are betting that faster approvals of new therapies will boost demand for clinical trials. Headlands operates more than 20 sites and has conducted over 5,000 trials in therapeutic areas including central nervous system disorders, mental health, vaccines, and metabolic diseases.